{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:45:42Z","timestamp":1792478742834,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejpb.2024.114209","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T17:22:44Z","timestamp":1707326564000},"page":"114209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Polymeric microneedles for the eye: An overview of advances and ocular applications for minimally invasive drug delivery"],"prefix":"10.1016","volume":"197","author":[{"given":"Madhura","family":"Mulkutkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Damani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Sawarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114209_b0005","unstructured":"WHO, Vision impairment and blindness. Blindness and Vision Impairment, World Heal. Organ. Website (2019). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment (accessed August 21, 2022)."},{"key":"10.1016\/j.ejpb.2024.114209_b0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaophthalmol.2021.0146","article-title":"A global assessment of eye health and quality of life a systematic review of systematic reviews","volume":"139","author":"Assi","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejpb.2024.114209_b0015","doi-asserted-by":"crossref","first-page":"e037648","DOI":"10.1136\/bmjopen-2020-037648","article-title":"Eye health and quality of life: an umbrella review protocol","volume":"10","author":"Assi","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejpb.2024.114209_b0020","doi-asserted-by":"crossref","DOI":"10.1111\/aos.15676","article-title":"Impact of vision on generic health-related quality of life \u2013 A systematic review","author":"Purola","year":"2023","journal-title":"Acta Ophthalmol. N\/a"},{"key":"10.1016\/j.ejpb.2024.114209_b0025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/aos.13903","article-title":"Quality of life and participation of young adults with a visual impairment aged 18\u201325 years: comparison with population norms","volume":"97","author":"Elsman","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2024.114209_b0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11136-011-0061-y","article-title":"The impact of low vision on activities of daily living, symptoms of depression, feelings of anxiety and social support in community-living older adults seeking vision rehabilitation services","volume":"21","author":"Kempen","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaophthalmol.2019.1230","article-title":"Association of Perceived Discrimination With Emotional Well-being in Older Adults With Visual Impairment","volume":"137","author":"Jackson","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejpb.2024.114209_b0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12877-022-03071-x","article-title":"Visual impairment as a predictor for deterioration in functioning: the Leiden 85-plus Study","volume":"22","author":"Verbeek","year":"2022","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.ejpb.2024.114209_b0045","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study","volume":"9","author":"Bourne","year":"2021","journal-title":"Lancet Glob. Heal."},{"key":"10.1016\/j.ejpb.2024.114209_b0050","unstructured":"UN, World Population Ageing 2019, 2019. http:\/\/link.springer.com\/chapter\/10.1007\/978-94-007-5204-7_6."},{"key":"10.1016\/j.ejpb.2024.114209_b0055","unstructured":"M.J. Burton, J. Ramke, A.P. Marques, R.R.A. Bourne, N. Congdon, I. Jones, H.B. Faal, et al., The Lancet Global Health Commission on Global Eye Health: vision beyond 2020, Lancet Glob. Heal. 9 (2021) e489\u2013e551. 10.1016\/S2214-109X(20)30488-5."},{"key":"10.1016\/j.ejpb.2024.114209_b0060","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2214-109X(17)30293-0","article-title":"Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis","volume":"5","author":"Bourne","year":"2017","journal-title":"Lancet Glob. Heal."},{"key":"10.1016\/j.ejpb.2024.114209_b0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/APO.0000000000000188","article-title":"The Global Issue of Vision Loss and What We Can Do About It: Jos\u00e9 Rizal Medal 2015","volume":"5","author":"Taylor","year":"2016","journal-title":"Asia-Pacific J. Ophthalmol. (philadelphia, Pa.)"},{"key":"10.1016\/j.ejpb.2024.114209_b0070","doi-asserted-by":"crossref","unstructured":"X. Yang, H. Chen, T. Zhang, X. Yin, J. Man, Q. He, M. Lu, Global, regional, and national burden of blindness and vision loss due to common eye diseases along with its attributable risk factors from 1990 to 2019: a systematic analysis from the global burden of disease study 2019., Aging (Albany. NY). 13 (2021) 19614\u201319642. 10.18632\/aging.203374.","DOI":"10.18632\/aging.203374"},{"key":"10.1016\/j.ejpb.2024.114209_b0075","unstructured":"World Health Organization, World report on vision Executive Summary, (2019) 1\u201312. https:\/\/www.who.int\/news-room\/detail\/08-10-2019-who-launches-first-world-report-on-vision (accessed September 4, 2022)."},{"key":"10.1016\/j.ejpb.2024.114209_b0080","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1021\/acs.jmedchem.9b01033","article-title":"Ocular disease therapeutics: design and delivery of drugs for diseases of the eye","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2024.114209_b0085","first-page":"1","article-title":"Emerging therapies and their delivery for treating age-related macular degeneration","author":"Thomas","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114209_b0090","article-title":"Herbal medicine for ocular diseases: An age old therapy and its future perspective","volume":"68","author":"Pokkalath","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114209_b0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: Challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114209_b0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/17425247.2016.1227783","article-title":"Recent perspectives on the delivery of biologics to back of the eye","volume":"14","author":"Joseph","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910594","article-title":"Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (Namd)","volume":"22","author":"Sarkar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0110","first-page":"1","article-title":"Ocular drug delivery: Advances, challenges and applications","author":"Addo","year":"2016","journal-title":"Ocul. Drug Deliv. Adv. Challenges Appl."},{"key":"10.1016\/j.ejpb.2024.114209_b0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"7","author":"Arepalli","year":"2021","journal-title":"Int. J. Retin. Vitr."},{"key":"10.1016\/j.ejpb.2024.114209_b0120","doi-asserted-by":"crossref","unstructured":"L. Bennett, Ocular Delivery of Proteins and Peptides BT - Ocular Drug Delivery: Advances, Challenges and Applications, in: R.T. Addo (Ed.), Springer International Publishing, Cham, 2016: pp. 117\u2013129. 10.1007\/978-3-319-47691-9_8.","DOI":"10.1007\/978-3-319-47691-9_8"},{"key":"10.1016\/j.ejpb.2024.114209_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119577","article-title":"The prominence of the dosage form design to treat ocular diseases","volume":"586","author":"Campos","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0130","doi-asserted-by":"crossref","unstructured":"T. Gadek, D. Lee, Topical drug delivery to the back of the eye, in: D. Prod (Ed.), Dev, Springer, Back Eye, 2011, pp. 111\u2013124. https:\/\/doi.org\/10.1007\/978-1-4419-9920-7_5.","DOI":"10.1007\/978-1-4419-9920-7_5"},{"key":"10.1016\/j.ejpb.2024.114209_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120332","article-title":"Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations","volume":"597","author":"Sripetch","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17425247.2019.1553953","article-title":"Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases","volume":"16","author":"Shatz","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0145","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17425247.2018.1496080","article-title":"Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye","volume":"15","author":"Wang","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory Complications of Intravitreal Anti-VEGF Injections","volume":"10","author":"Cox","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2024.114209_b0155","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2024.114209_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/17425247.2018.1471059","article-title":"Drug delivery using microneedle patches: not just for skin","volume":"15","author":"Lee","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0165","doi-asserted-by":"crossref","unstructured":"A.S. Rzhevskiy, T.R.R. Singh, R.F. Donnelly, Y.G. Anissimov, Microneedles as the technique of drug delivery enhancement in diverse organs and tissues, Elsevier B.V, 2018. 10.1016\/j.jconrel.2017.11.048.","DOI":"10.1016\/j.jconrel.2017.11.048"},{"key":"10.1016\/j.ejpb.2024.114209_b0170","first-page":"67","article-title":"Non-dermal applications of microneedle drug delivery systems, Drug Deliv","volume":"12","author":"Panda","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0175","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17425247.2022.2118711","article-title":"Advances in microneedles for non-transdermal applications","volume":"19","author":"Cao","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0180","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.07-0066","article-title":"Coated microneedles for drug delivery to the eye","volume":"48","author":"Jiang","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0185","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1167\/iovs.14-15257","article-title":"Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0190","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/ICO.0000000000002182","article-title":"A Fixed-Depth Microneedle Enhances Reproducibility and Safety for Corneal Gene Therapy","volume":"39","author":"Gilger","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2024.114209_b0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jop.2017.0121","article-title":"Intravitreal, subretinal, and suprachoroidal injections: Evolution of microneedles for drug delivery","volume":"34","author":"Hartman","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0200","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","article-title":"Minimally invasive microneedles for ocular drug delivery","volume":"14","author":"Thakur Singh","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116907","article-title":"Applications of microneedles in delivering drugs for various ocular diseases","volume":"237","author":"Gupta","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0210","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3762\/bjnano.13.98","article-title":"Microneedle-based ocular drug delivery systems \u2013 recent advances and challenges","volume":"13","author":"Gadzi\u0144ski","year":"2022","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114209_b0215","doi-asserted-by":"crossref","unstructured":"S.R. Patel, H.F. Edelhauser, M.R. Prausnitz, Targeted Drug Delivery to the Eye Enabled by Microneedles, in: U.B. Kompella, H.F. Edelhauser (Eds.), Drug Prod. Dev. Back Eye, Springer US, Boston, MA, 2011: pp. 331\u2013360. 10.1007\/978-1-4419-9920-7_14.","DOI":"10.1007\/978-1-4419-9920-7_14"},{"key":"10.1016\/j.ejpb.2024.114209_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/mi11110961","article-title":"Microneedles: Characteristics, materials, production methods and commercial development","volume":"11","author":"Tucak","year":"2020","journal-title":"Micromachines"},{"key":"10.1016\/j.ejpb.2024.114209_b0225","doi-asserted-by":"crossref","DOI":"10.1007\/s12039-019-1666-x","article-title":"Microneedle-based drug delivery : materials of construction","author":"Bhatnagar","year":"2019","journal-title":"J. Chem. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116907","article-title":"Applications of microneedles in delivering drugs for various ocular diseases","volume":"237","author":"Gupta","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0235","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11095-008-9756-3","article-title":"Intrascleral Drug Delivery to the Eye Using Hollow Microneedles","volume":"26","author":"Jiang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0240","unstructured":"Clearside Biomedical, SCS Microinjector\u00ae A Transformative Solution Precisely Targeting the Suprachoroidal Space. https:\/\/clearsidebio.com\/technology\/scs-microinjector\/ (accessed August 16, 2022)."},{"key":"10.1016\/j.ejpb.2024.114209_b0245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2015.04.041","article-title":"Impact insertion of transfer-molded microneedle for localized and minimally invasive ocular drug delivery","volume":"209","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114209_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/gels8020082","article-title":"Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.ejpb.2024.114209_b0255","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/pharmaceutics15030734","article-title":"Updates on biodegradable formulations for ocular drug delivery","volume":"15","author":"Tsung","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0260","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/187221130802140707093509","article-title":"Episcleral, intrascleral, and suprachoroidal routes of ocular drug delivery - recent research advances and patents","volume":"8","author":"Gilger","year":"2014","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2024.114209_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0275","doi-asserted-by":"crossref","unstructured":"T. Ciulla, S. Yeh, Microinjection via the Suprachoroidal Space: A Review of a Novel Mode of Administration, Am. J. Manag. Care 28 (2022) S243\u2013S252. 10.37765\/AJMC.2022.89270.","DOI":"10.37765\/ajmc.2022.89270"},{"key":"10.1016\/j.ejpb.2024.114209_b0280","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2014.10.010","article-title":"The suprachoroidal pathway: a new drug delivery route to the back of the eye","volume":"20","author":"Rai","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2024.114209_b0285","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114209_b0290","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Invest. Ophthalmol. vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107824","article-title":"Collagenase injection into the suprachoroidal space of the eye to expand drug delivery coverage and increase posterior drug targeting","volume":"189","author":"Jung","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0300","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114209_b0305","first-page":"433","article-title":"Injectable depot forming thermoresponsive hydrogel for sustained intrascleral delivery of sunitinib using hollow microneedles","volume":"38","author":"Gade","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0310","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","article-title":"Six-month sustained delivery of anti-VEGF from in-situ forming hydrogel in the suprachoroidal space","volume":"352","author":"Jung","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114209_b0315","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Investig. Ophthalmol. vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release off. J. Control. Release Soc."},{"key":"10.1016\/j.ejpb.2024.114209_b0325","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jphp.12152","article-title":"Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery","volume":"66","author":"Thakur","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114209_b0330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coph.2017.07.007","article-title":"Microneedles for enhanced transdermal and intraocular drug delivery","volume":"36","author":"Moffatt","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114209_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2018.09.021","article-title":"Depthwise-controlled Scleral Insertion of Microneedles for Drug Delivery to the Back of the Eye","author":"Park","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0340","doi-asserted-by":"crossref","first-page":"e2102599","DOI":"10.1002\/adhm.202102599","article-title":"Self-Plugging Microneedle (SPM) for Intravitreal Drug Delivery","volume":"11","author":"Lee","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ejpb.2024.114209_b0345","doi-asserted-by":"crossref","unstructured":"M. Cui, M. Zheng, C. Wiraja, S.W.T. Chew, A. Mishra, V. Mayandi, R. Lakshminarayanan, C. Xu, Ocular Delivery of Predatory Bacteria with Cryomicroneedles Against Eye Infection., Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger. 8 (2021) e2102327. 10.1002\/advs.202102327.","DOI":"10.1002\/advs.202102327"},{"key":"10.1016\/j.ejpb.2024.114209_b0350","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther. off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0355","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jiec.2022.11.072","article-title":"In-situ nanomicelle forming microneedles of poly NIPAAm-b-poly glutamic acid for trans-scleral delivery of dexamethasone","volume":"119","author":"Alimardani","year":"2023","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.ejpb.2024.114209_b0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0885328211433778","article-title":"PDMS embedded microneedles as a controlled release system for the eye","volume":"28","author":"Mahadevan","year":"2013","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.ejpb.2024.114209_b0365","doi-asserted-by":"crossref","unstructured":"O. Khandan, A. Famili, M.Y. Kahook, M.P. Rao, Titanium-Based, Fenestrated, In-plane microneedles for passive ocular drug delivery omid, in: 2012 Annu. Int. Conf. IEEE Eng. Med. Biol. Soc., 2012: pp. 6572\u20136575.","DOI":"10.1109\/EMBC.2012.6347500"},{"key":"10.1016\/j.ejpb.2024.114209_b0370","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.snb.2015.09.071","article-title":"Fenestrated microneedles for ocular drug delivery","volume":"223","author":"Khandan","year":"2016","journal-title":"Sensors Actuators, B Chem."},{"key":"10.1016\/j.ejpb.2024.114209_b0375","first-page":"1","article-title":"Translation of polymeric microneedles for treatment of human diseases: Recent trends","volume":"13","author":"Yadav","year":"2021","journal-title":"Progr. Challenges Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0380","first-page":"1","article-title":"Polymeric microneedle arrays: versatile tools for an innovative approach to drug administration","volume":"2","author":"Dardano","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0385","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2022.05.045","article-title":"Dissolving microneedles: Applications and growing therapeutic potential","volume":"348","author":"Sartawi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114209_b0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejpb.2020.12.020","article-title":"European Journal of Pharmaceutics and Biopharmaceutics Microneedles for Extended Transdermal Therapeutics : A Route to Advanced Healthcare","volume":"159","author":"Pahal","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0395","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2020.12.006","article-title":"Microneedle array systems for long-acting drug delivery","volume":"159","author":"Vora","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0400","doi-asserted-by":"crossref","unstructured":"Z. Chen, J. He, J. Qi, Q. Zhu, W. Wu, Y. Lu, Long-acting microneedles\u00a0: a progress report of the state-of-the-art techniques, 00 (2020). 10.1016\/j.drudis.2020.05.006.","DOI":"10.1016\/j.drudis.2020.05.006"},{"key":"10.1016\/j.ejpb.2024.114209_b0405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101601","article-title":"Dissolving microneedles developed in association with nanosystems: A scoping review on the quality parameters of these emerging systems for drug or protein transdermal delivery","volume":"13","author":"Weimer","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0410","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030472","article-title":"Optimal design of novel microemulsions-based two-layered dissolving microneedles for delivering fluconazole in treatment of fungal eye infection","volume":"14","author":"Suriyaamporn","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mabi.202000089","article-title":"Self-adhesive microneedles with interlocking features for sustained ocular drug delivery","volume":"20","author":"Amer","year":"2020","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.ejpb.2024.114209_b0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1115\/1.4048481","article-title":"Hydrogel-forming microneedle arrays for sustained and controlled ocular drug delivery","volume":"3","author":"Amer","year":"2020","journal-title":"J. Eng. Sci. Med. Diagnostics Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/smll.202104657","article-title":"A rapid corneal healing microneedle for efficient ocular drug delivery","volume":"18","author":"Shi","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.ejpb.2024.114209_b0430","article-title":"Computer-aided rational design for optimally Gantrez\u00ae S-97 and hyaluronic acid-based dissolving microneedles as a potential ocular delivery system","volume":"61","author":"Suriyaamporn","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114209_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06981-w","article-title":"Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery","volume":"9","author":"Than","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2024.114209_b0440","first-page":"473","article-title":"Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles, Drug Deliv","volume":"8","author":"Bhatnagar","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0445","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1080\/03639045.2020.1776317","article-title":"Microneedle ocular patch: fabrication, characterization, and ex-vivo evaluation using pilocarpine as model drug","volume":"46","author":"Roy","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0450","doi-asserted-by":"crossref","unstructured":"G. Roy, R.D. Galigama, V.S. Thorat, L. Sruthi, S. Roy, P. Garg, V. Vamsi, K. Venuganti, Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis, Elsevier B.V., 2019. 10.1016\/j.ijpharm.2019.118808.","DOI":"10.1016\/j.ijpharm.2019.118808"},{"key":"10.1016\/j.ejpb.2024.114209_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121305","article-title":"Microneedle scleral patch for minimally invasive delivery of triamcinolone to the posterior segment of eye","volume":"612","author":"Roy","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0460","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejpb.2021.05.022","article-title":"Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye","volume":"165","author":"Wu","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0465","article-title":"Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye","author":"Wu","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0470","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13346-021-01032-2","article-title":"Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections","author":"Albadr","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.212767","article-title":"Nanosuspension-loaded dissolving bilayer microneedles for hydrophobic drug delivery to the posterior segment of the eye","volume":"137","author":"Wu","year":"2022","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ejpb.2024.114209_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061622","article-title":"Transscleral Delivery of Dexamethasone-Loaded Microparticles Using a Dissolving Microneedle Array","volume":"15","author":"Fitaihi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114209_b0485","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/jop.2021.0089","article-title":"Sustained Release Biodegradable Microneedles of Difluprednate for Delivery to Posterior Eye","volume":"38","author":"Shelley","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2024.114209_b0490","unstructured":"R. Prausnitz, Mark, N. Jiang, F. Edelhauser, Henry, WO2007131050 - Method for Drug Delivery to Ocular Tissue using Microneedle, (n.d.). https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2007131050&_cid=P11-LRX0TB-14345-1 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0495","unstructured":"V.V.V. Krishna, G. Prashant, R. Girdhari, B. Shubhmita, An Ocular Drug Delivery Device, (n.d.). https:\/\/iprsearch.ipindia.gov.in\/PublicSearch\/PublicationSearch\/PatentDetails (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0500","unstructured":"R. Prausnitz, Mark, N. Jiang, F. Edelhauser, Henry, EP2563429 - Device for Delivery of a Drug to Ocular Tissue using Microneedle, (n.d.). https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=EP76609188&_cid=P11-LRX2RW-24609-1 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0505","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.5.6.14","article-title":"Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis","volume":"5","author":"Goldstein","year":"2016","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114209_b0510","unstructured":"NCT01789320, Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis. https:\/\/clinicaltrials.gov\/study\/NCT01789320 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0515","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide, Cls-Ta, for Macular Edema due to Noninfectious Uveitis: A Randomized, Phase 2 Study (DOGWOOD)","volume":"39","author":"Yeh","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ejpb.2024.114209_b0520","unstructured":"NCT02255032, Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis (DOGWOOD). https:\/\/clinicaltrials.gov\/study\/NCT02255032 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0525","doi-asserted-by":"crossref","unstructured":"K.W. Price, T.A. Albini, S. Yeh, Suprachoroidal Injection of Triamcinolone- Review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis., US Ophthalmic Rev. 13 (2020) 76\u201379. 10.17925\/usor.2020.13.2.76.","DOI":"10.17925\/USOR.2020.13.2.76"},{"key":"10.1016\/j.ejpb.2024.114209_b0530","unstructured":"NCT02595398, Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis (PEACHTREE). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02595398 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0535","unstructured":"NCT04690608, Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema and CRVO (Resistant). https:\/\/clinicaltrials.gov\/study\/NCT04690608 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0540","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/OPTH.S361636","article-title":"Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.ejpb.2024.114209_b0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12886-023-02808-5","article-title":"Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study","volume":"23","author":"Ali","year":"2023","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ejpb.2024.114209_b0550","unstructured":"NCT05038072, The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion. https:\/\/clinicaltrials.gov\/study\/NCT05038072 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0555","unstructured":"NCT02980874, Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO (SAPPHIRE). https:\/\/clinicaltrials.gov\/study\/NCT02980874 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0560","unstructured":"NCT06007690, A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06007690 (accessed January 26, 2024)."},{"key":"10.1016\/j.ejpb.2024.114209_b0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/polym13162815","article-title":"A comprehensive review of microneedles: Types, materials, processes, characterizations and applications","volume":"13","author":"Aldawood","year":"2021","journal-title":"Polymers (basel)."},{"key":"10.1016\/j.ejpb.2024.114209_b0570","doi-asserted-by":"crossref","DOI":"10.1177\/20417314221085390","article-title":"Application of microneedle patches for drug delivery; doorstep to novel therapies","volume":"13","author":"Nazary Abrbekoh","year":"2022","journal-title":"J. Tissue Eng."},{"key":"10.1016\/j.ejpb.2024.114209_b0575","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejpb.2017.04.029","article-title":"Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo","volume":"117","author":"Vicente-Perez","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114209_b0580","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jconrel.2016.01.051","article-title":"Micropore closure kinetics are delayed following microneedle insertion in elderly subjects","volume":"225","author":"Kelchen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114209_b0585","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and Closure Kinetics of the Suprachoroidal Space Following Microneedle Injection of Liquid Formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0590","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance Kinetics and Clearance Routes of Molecules From the Suprachoroidal Space After Microneedle Injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. vis. Sci."},{"key":"10.1016\/j.ejpb.2024.114209_b0595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.exer.2016.10.011","article-title":"Distribution of particles, small molecules and polymeric formulation excipients in the suprachoroidal space after microneedle injection","volume":"153","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0600","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exer.2016.03.008","article-title":"Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries","volume":"145","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0605","doi-asserted-by":"crossref","unstructured":"R.F. Donnelly, Clinical Translation and Industrial Development of Microneedle\u2010based Products, in: M.T.C.M. Ryan F. Donnelly, Thakur Raghu Raj Singh, Eneko Larra\u00f1eta (Ed.), Microneedles Drug Vaccine Deliv. Patient Monit., John Wiley & Sons., 2018: pp. 307\u2013322. 10.1002\/9781119305101.ch11.","DOI":"10.1002\/9781119305101.ch11"},{"key":"10.1016\/j.ejpb.2024.114209_b0610","first-page":"313","article-title":"Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation, Drug Deliv","volume":"5","author":"Lutton","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0615","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737167.2018.1485100","article-title":"Therapeutic applications and pharmacoeconomics of microneedle technology","volume":"18","author":"Richter-Johnson","year":"2018","journal-title":"Expert Rev. Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.ejpb.2024.114209_b0620","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","article-title":"Microneedle patches: Usability and acceptability for self-vaccination against influenza","volume":"32","author":"Norman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2024.114209_b0625","doi-asserted-by":"crossref","unstructured":"N.G. Rouphael, M. Paine, R. Mosley, S. Henry, D. V. McAllister, H. Kalluri, W. Pewin, P.M. Frew, T. Yu, N.J. Thornburg, S. Kabbani, L. Lai, E. V. Vassilieva, I. Skountzou, R.W. Compans, M.J. Mulligan, M.R. Prausnitz, A. Beck, S. Edupuganti, S. Heeke, C. Kelley, W. Nesheim, The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial, Lancet 390 (2017) 649\u2013658. 10.1016\/S0140-6736(17)30575-5.","DOI":"10.1016\/S0140-6736(17)30575-5"},{"key":"10.1016\/j.ejpb.2024.114209_b0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.02.040","article-title":"Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects","volume":"128","author":"Arya","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114209_b0635","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.9.11.27","article-title":"Clinical Characterization of Suprachoroidal Injection Procedure Utilizing a Microinjector across Three Retinal Disorders","volume":"9","author":"Wan","year":"2020","journal-title":"Transl. vis. Sci. Technol."},{"key":"10.1016\/j.ejpb.2024.114209_b0640","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2024.114209_b0645","unstructured":"FDA, Regulatory Considerations for Microneedling Products Guidance for Industry and Food and Drug Administration Staff Preface Public Comment, (2020) 1\u201312. https:\/\/www.regulations.gov."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:42:10Z","timestamp":1738438930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":129,"alternative-id":["S0939641124000353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114209","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric microneedles for the eye: An overview of advances and ocular applications for minimally invasive drug delivery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114209"}}